RxDoctor Payments Data

Deborah Bernstein, MD

Ophthalmology · Waukesha, WINPI 1326005919

Payments from drug & device makers

$2,323in general payments, 2019–2025

Across 97 payments — averaging $23.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$809
  • AbbVie$276
  • Novartis$227
  • Glaukos Corporation$210
  • Bausch & Lomb Americas Inc.$163
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$95
  • plus $544 from 12 others

What the payments were for

  • Food & beverage$2,323100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,323 in reported general payments places this provider in the 80th percentile of 337 ophthalmology providers in Wisconsin.

See all ophthalmology providers in Wisconsin

Medicare billing

Part B allowed, 2024
$336,358
Medicare patients
894
Services billed
2,955

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine52$49,186
LumiganBimatoprost47$24,673
XiidraLifitegrast17$18,926
Cyclosporine20$15,753
Prednisolone Acetate261$14,630
Ketorolac Tromethamine259$10,985
Latanoprost516$7,283
SimbrinzaBrinzolamide/Brimonidine Tart17$4,681
Travoprost26$4,214
Timolol Maleate161$2,320
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat32$714
ErythromycinErythromycin Base37$460
Brimonidine Tartrate52$342
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha14$168
Doxycycline Monohydrate11$109

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$276$73,85899 claims
Bausch & Lomb Americas Inc.Xiidra$163$18,92617 claims
AlconSimbrinza$809$4,68117 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 337 ophthalmology providers in Wisconsin.

Other ophthalmology in Waukesha

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →